KR20200117957A - A composition for preventing or treating atopic dermatitis comprising the extract of corn silk - Google Patents

Abstract

The present invention relates to: a pharmaceutical composition for preventing or treating atopic dermatitis containing a corn silk extract or a fraction thereof; a method for treating atopic dermatitis comprising a step of administering the pharmaceutical composition to an individual; a food composition for alleviating atopic dermatitis containing the corn silk extract or the fraction thereof; a quasi-drug composition for preventing or alleviating atopic dermatitis containing the corn silk extract or the fraction thereof; and a cosmetic composition for preventing or alleviating atopic dermatitis containing the corn silk extract or the fraction thereof. The corn silk extract of the present invention not only exhibits an anti-inflammatory effect, but also has an effect of inhibiting one of the causes of atopic dermatitis, so that the corn silk extract of the present invention can be widely used in the prevention and treatment of atopic dermatitis.

Description

A composition for preventing or treating atopic dermatitis comprising the extract of corn silk}

The present invention relates to a composition for preventing or treating atopic dermatitis comprising a corn beard extract, and more specifically, the present invention administering to a subject a pharmaceutical composition for preventing or treating atopic dermatitis comprising a corn beard extract or a fraction thereof A method of treating atopic dermatitis comprising the step of, a food composition for improving atopic dermatitis comprising a corn beard extract or a fraction thereof, a quasi-drug composition for preventing or improving atopic dermatitis comprising a corn beard extract or a fraction thereof, and a corn beard extract or It relates to a cosmetic composition for preventing or improving atopic dermatitis comprising a fraction thereof.

Corn ( Zea mays L.) is a by-product of corn, which is the thread-like part that wraps the fruit and is called jade mibal and jade calligraphy. These corn beards contain fatty oils, fats, bitter glycosides, saponins, alkaloids, and macin, as well as inositol, cryptoxanthine, pantothenic acid, vitamin C, malic acid, tartaric acid, glucose, xylan, etc., and in particular, a large amount of vitamin K is included. Has been. In addition, there are maysin, apimaysin, and methoxymaysin as the flavonoids, one of the ingredients contained in corn beard. In addition, this mecine has been reported to inhibit the growth of corn earworm, cytotoxic effect on tumor cell lines, and radical scavenging activity. Recently, studies have been published that corn beard extract has antioxidant activity and skin protection effect from UV, and research results on a method of extracting large amounts of the active ingredients, mayine and similar substances from corn beard, have also been reported.

The skin is the first organ to function as a physical barrier that protects the body against various environmental factors, and various environmental stimuli trigger the activation of the immune system. In addition, atopic dermatitis, one of various skin diseases of the skin, is a chronic and recurrent skin disease that generally occurs in infants and children. Symptoms such as severe itching and skin eczema continue to worsen, relieve, and recur due to various causes. do. In industrialized countries, the incidence of atopic dermatitis continues to increase, reaching 1-5% of adults and 10-20% of infants and children, and research to solve this problem is being actively conducted worldwide.

Accordingly, by using various components such as immunomodulatory substances, substances exhibiting anti-inflammatory effects, substances that inhibit atopy-inducing signal transduction, etc., formulations exhibiting atopic treatment effects are being developed. In particular, nonsteroidal systems and steroids with excellent anti-inflammatory effects Active research is being conducted on substances of the system, but due to various causes, such as high manufacturing cost, atopic treatment effect, and side effects not verified or serious side effects, atopic treatments have not been commercialized. It is not possible.

On the other hand, in order to solve these shortcomings, research is being actively conducted to develop a herbal preparation that exhibits atopic therapeutic effect targeting natural products that have not been found to exhibit side effects. For example, Korean Patent No. 1528135 discloses a pharmaceutical composition for the prevention or treatment of atopic dermatitis comprising an extract of white rose petals or a pyrogallol compound isolated therefrom as an active ingredient. A composition for preventing or treating atopic dermatitis comprising an extract extracted from herbal medicinal herbs including Baeja Oh, Jibuja, Casualty, Eoseongcho, Hyeonggae, Gosam, Rhubarb, Jacho, Gaja, and Cheonhwabun as an active ingredient is disclosed, and Korean Patent No. 1814389 No. 1 discloses a cosmetic composition comprising a Bunhaengcho extract and having antioxidant activity, anti-inflammatory and atopic-inducing inhibitory effects, and Korean Patent No. 1828204 discloses cornus milk extract, brier extract, cypress extract, cypress extract, and Yule leaf extract. An anti-atopic composition comprising is disclosed. However, while the results obtained through these natural product studies show excellent safety, there is a disadvantage that a long treatment time is required to treat atopy.

Under this background, the present inventors have made extensive research efforts to develop a formulation that can safely and more effectively treat atopic dermatitis, and as a result, it has been confirmed that corn beard extract can effectively treat atopic dermatitis, and has completed the present invention. .

One object of the present invention is to provide a pharmaceutical composition for preventing or treating atopic dermatitis, comprising a corn beard extract or a fraction thereof.

Another object of the present invention is to provide a method for treating atopic dermatitis comprising administering the pharmaceutical composition to a suspected subject of atopic dermatitis except for humans.

Another object of the present invention is to provide a food composition for improving atopic dermatitis comprising a corn beard extract or a fraction thereof.

Another object of the present invention is to provide a quasi-drug composition for preventing or improving atopic dermatitis comprising a corn beard extract or a fraction thereof.

Another object of the present invention is to provide a cosmetic composition for preventing or improving atopic dermatitis comprising a corn beard extract or a fraction thereof.

The present inventors have conducted research on natural products with proven safety in order to develop a formulation that can exhibit the effect of treating atopic dermatitis more effectively while being safe, and as a result, attention has been paid to corn beard.

In order to check whether the corn beard extract obtained by extracting the corn beard with ethanol exhibits an effective effect on inflammatory diseases, as a result of treatment on LPS-treated macrophages, the amount of production increased by LPS stimulation in the macrophages. It was confirmed that the level of NO (nitric oxide) and TNF-α (tumor necrosis factor-α) was reduced by the corn beard extract. Accordingly, it was attempted to confirm whether the corn beard extract exhibited an effective effect against atopic dermatitis. That is, in epithelial cells stimulated with IFN-γ and TNF-α, the production of TARC (thymus and activation regualted chemokine), a type of inflammatory cytokine, is increased, and this increase in the production of inflammatory cytokines is one of the causes of atopic dermatitis. Is known. The IFN-γ and TNF-α-stimulated epithelial cells were treated with corn beard extract, and as a result, it was confirmed that the amount of TARC produced was reduced. As a result, it was found that the corn beard extract provided by the present invention not only suppresses inflammation, but also suppresses the causative symptoms of atopic dermatitis, thus exhibiting an effective effect in the prevention or treatment of atopic dermatitis.

As such, it has not been known before that the corn beard extract exhibits a therapeutic effect on atopic dermatitis, and was first identified by the present inventors.

One embodiment of the present invention for achieving the above object provides a pharmaceutical composition for the prevention or treatment of atopic dermatitis comprising a corn beard extract or a fraction thereof.

The term "corn silk" of the present invention is called jade mibal, jade calligraphy, etc., and means a thread-like part that wraps the fruit of corn. In addition to fatty oils, fats, bitter glycosides, saponins, alkaloids, and macin, the corn beard contains inositol, cryptoxanthine, pantothenic acid, vitamin C, malic acid, tartaric acid, glucose, xylan, etc., and in particular, a large amount of vitamin K is included. (Cha SM, et al., Effect of particle size on physico-chemical properties and antioxidant activity of corn silk powder. Korean J. Crop Sci. 57: 41-50 (2012)). In addition, there are maysin, apimaysin, and methoxymaysin as the flavonoids, which are one of the ingredients contained in corn beard, of which maysin is the most common substance contained in corn beard. It is known that this mecine exhibits cytotoxic effects and radical scavenging activity against tumor cell lines (Ku KM, et al., Antioxidant activity and functional components of corn silk (Zea mays L.). Korean J. Plant Res. 22: 323-329 (2009)).

In the present invention, the corn beard may be used by purchasing commercially sold ones, or those harvested or grown in nature, but is not limited thereto.

In terms of the present invention, the term "extract" refers to an extract obtained by extracting corn beard, a dilution or concentrate of the extract, a dried product obtained by drying the extract, a crude or purified product of the extract, or a mixture thereof, etc. It includes extracts of all formulations that can be formed using itself and extracts.

In the present invention, the corn beard extract may be named "NICS-1" or "NICS-3" interchangeably.

In the corn beard extract of the present invention, a method of extracting the mixture is not particularly limited, and may be extracted according to a method commonly used in the art. Non-limiting examples of the extraction method include a hot water extraction method, an ultrasonic extraction method, a filtration method, a reflux extraction method, and the like, and these may be performed alone or in combination of two or more methods.

In the present invention, the type of solvent used for the extraction is not particularly limited, and any solvent known in the art may be used. Non-limiting examples of the extraction solvent may include water, alcohol, or a mixed solvent thereof, and these may be used alone or in combination of one or more, and specifically water may be used. When alcohol is used as a solvent, an alcohol having 1 to 4 carbon atoms may be specifically used.

As used herein, the term "fraction" means a result obtained by performing fractionation in order to separate a specific component or a specific group of components from a mixture containing several different constituents.

The fractionation method for obtaining the fraction in the present invention is not particularly limited, and may be performed according to a method commonly used in the art. Non-limiting examples of the fractionation method include a solvent fractionation method performed by treating various solvents, an ultrafiltration fractionation method performed by passing an ultrafiltration membrane having a constant molecular weight cut-off value, and various chromatography (size, charge, hydrophobicity). Or a chromatographic fractionation method for performing separation according to affinity), and combinations thereof. Specifically, there may be mentioned a method of obtaining a fraction from the extract by treating the extract obtained by extracting the corn beard of the present invention with a predetermined solvent.

In the present invention, the type of fractionation solvent used to obtain the fraction is not particularly limited, and any solvent known in the art may be used. Non-limiting examples of the fractionation solvent include polar solvents such as water and alcohols having 1 to 4 carbon atoms; Non-polar solvents such as hexane, ethyl acetate, chloroform, and dichloromethane; Or a mixed solvent of these, etc. are mentioned. These may be used alone or in combination of one or more, but are not limited thereto.

In addition, the extract or fraction may be prepared and used in a dry powder form after extraction, but is not limited thereto.

The term of the present invention, "Atopic dermatitis (AD)" is a kind of autoimmune skin disease, and refers to a skin disease accompanied by skin swelling, eczema, and itching. It is known that both environmental and genetic factors are involved in the onset of atopic dermatitis, but the exact pathogenesis has not been identified. In the present invention, the atopic dermatitis may be named interchangeably with "AD".

The term "prevention" of the present invention means any action of suppressing or delaying atopic dermatitis by administration of a composition comprising the extract.

The term "treatment" of the present invention refers to any action in which symptoms of atopic dermatitis are improved or advantageously changed by administration of a composition comprising the extract.

According to an embodiment of the present invention, corn beard extracts (NICS-1 and NICS-3) of the present invention did not show cytotoxicity in macrophages (RAW 264.7 cells) and epithelial cells (HaCaT cells), and macrophages (RAW 264.7 cells), as a result of analyzing the effect of LPS stimulation on the production of NO by LPS stimulation, the amount of NO production in the LPS alone treatment increased significantly compared to the untreated group, but corn salt extracts (NICS-1 and NICS-3) were used. In the treated group, it was confirmed that the amount of NO production decreased in a concentration-dependent manner (FIG. 1). In addition, as a result of analyzing the effect of the corn beard extract (NICS-1 and NICS-3) of the present invention based on the amount of TNF-α produced in LPS-stimulated macrophages (RAW 264.7 cells), corn beard extract (NICS -1 and NICS-3) were confirmed to inhibit the secretion of TNF-α in RAW 264.7 cells (Fig. 2). Finally, it was confirmed that the corn beard extract (NICS-1 and NICS-3) exhibited an effect of inhibiting TARC production in HaCaT cells, which are epithelial cells (FIG. 3).

Since inflammatory cytokines generated excessively in epithelial cells are known as one of the causes of atopic dermatitis, from the above results, it was found that the corn beard extract of the present invention exhibits a preventive or therapeutic effect of atopic dermatitis.

The pharmaceutical composition of the present invention may include 0.001 to 80, specifically 0.001 to 70, more specifically 0.001 to 60% by weight of the extract based on the total weight of the composition, but is not limited thereto.

In addition, the pharmaceutical composition may further include a pharmaceutically acceptable carrier, excipient, or diluent commonly used in the manufacture of pharmaceutical compositions, and the carrier may include a non-naturally occurring carrier. have. Examples of the carrier, excipient and diluent include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline Cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oils.

In addition, the pharmaceutical compositions are each tablet, pill, powder, granule, capsule, suspension, solution, emulsion, syrup, sterilized aqueous solution, non-aqueous solvent, suspension, emulsion, freeze-dried, transdermal, respectively, according to a conventional method. It can be formulated and used in the form of absorbents, gels, lotions, ointments, creams, patches, cataplasmas, pastes, sprays, skin emulsions, skin suspensions, transdermal delivery patches, drug-containing bandages or suppositories. Specifically, when formulated, it may be prepared using diluents or excipients such as fillers, weight agents, binders, wetting agents, disintegrants, surfactants, etc. that are commonly used. Solid preparations for oral administration include, but are not limited to, tablets, pills, powders, granules, capsules, and the like. These solid preparations may be prepared by mixing at least one or more excipients, for example starch, calcium carbonate, sucrose, lactose, gelatin, and the like. In addition, in addition to simple excipients, lubricants such as magnesium stearate and talc may be used. It can be prepared by adding various excipients, such as wetting agents, sweetening agents, fragrances, preservatives, and the like, in addition to oral liquids and liquid paraffin. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized formulations, and suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyloleate, and the like may be used. As a base for suppositories, Witepsol, Macrogol, Tween 61, cacao butter, laurin paper, glycerogelatin, and the like can be used.

Another embodiment of the present invention provides a method for treating atopic dermatitis, comprising administering the pharmaceutical composition to a suspected individual of atopic dermatitis other than humans.

The term "administration" of the present invention refers to the act of introducing a composition comprising the extract to an individual by an appropriate method.

As used herein, the term "individual" refers to all animals such as rats, mice, and livestock, including humans who have or may develop atopic dermatitis. As a specific example, it may be a mammal including a human.

The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. The term "pharmaceutically effective amount" means an amount sufficient to treat a disease with a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is the type and severity of the subject, age, sex, activity of the drug, Sensitivity to drugs, time of administration, route of administration and rate of excretion, duration of treatment, factors including drugs used concurrently, and other factors well known in the medical field. For example, the corn beard extract may be administered at a dose of 0.01 to 500 mg/kg per day, specifically 10 to 100 mg/kg, and the administration may be administered once or several times a day.

The pharmaceutical composition may be administered as an individual therapeutic agent or administered in combination with other therapeutic agents, and may be administered sequentially or simultaneously with a conventional therapeutic agent. And can be administered single or multiple. It is important to administer an amount capable of obtaining the maximum effect in a minimum amount without side effects in consideration of all the above factors, and can be easily determined by a person skilled in the art.

In addition, the pharmaceutical composition may be administered orally or parenterally (for example, intravenous, subcutaneous, intraperitoneal or topical application) according to a desired method, and the dosage may be the patient's condition and weight, the degree of disease , It depends on the drug form, administration route and time, but may be appropriately selected by those skilled in the art.

Another embodiment of the present invention provides a food composition for improving atopic dermatitis comprising a corn beard extract or a fraction thereof.

At this time, the definition of the corn beard, extract, fraction, and atopic dermatitis are as described above.

The term "improvement" of the present invention means any action of at least reducing the severity of a parameter, such as a symptom, related to the condition to be treated by administration of a composition comprising the extract.

As used herein, the term "food" refers to meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages , Vitamin complexes, health functional foods and health foods, and all foods in the usual sense are included.

Since the food composition of the present invention is derived from corn beard that can be consumed on a daily basis, a high atopic dermatitis improvement effect can be expected, and thus it can be very usefully used for health promotion purposes.

The health function (functional food) is the same term as food for special health use (FoSHU).In addition to nutritional supply, the term "functional food" refers to medicine that is processed so that the bioregulatory function is effectively displayed. Means food. Here, the term'function (sex)' means to control nutrients for the structure and function of the human body or to obtain useful effects for health purposes such as physiological actions. The food of the present invention can be prepared by a method commonly used in the art, and during the production, raw materials and ingredients commonly added in the art may be added to prepare the food product. In addition, the formulation of the food may be prepared without limitation as long as it is a formulation recognized as a food.

The food composition of the present invention can be prepared in various forms, and unlike general drugs, it has the advantage of not having side effects that may occur when taking drugs for a long time using natural substances as raw materials, and is excellent in portability. The food of the present invention can be ingested as an adjuvant for enhancing the effect of improving atopic dermatitis.

The health food refers to a food having an active health maintenance or promotion effect compared to a general food, and a health supplement food refers to a food for health supplement purposes. In some cases, the terms health functional food, health food, and health supplement are used interchangeably.

Specifically, the health functional food is a food prepared by adding the compound of the present invention to food materials such as beverages, teas, spices, gums, confectionery, or encapsulating, powdering, and suspending. It means bringing about an effect, but unlike general drugs, it has the advantage of having no side effects that may occur when taking the drug for a long time by using food as a raw material.

The food composition may further include a physiologically acceptable carrier, and the kind of carrier is not particularly limited, and any carrier commonly used in the art may be used.

In addition, the food composition may include additional ingredients that are commonly used in food compositions to improve smell, taste, vision, and the like. For example, vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, panthotenic acid, and the like may be included. In addition, minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu), and chromium (Cr); And amino acids such as lysine, tryptophan, cysteine, and valine.

In addition, the food composition includes preservatives (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate, etc.), disinfectants (bleaching and highly bleaching, sodium hypochlorite, etc.), antioxidants (butylhydroxyanisole (BHA), butylhydride, etc.) Oxytoleuene (BHT), etc.), coloring agent (tar color, etc.), coloring agent (sodium nitrite, sodium nitrite, etc.), bleach (sodium sulfite), seasoning (MSG sodium glutamate, etc.), sweetener (dulsin, cyclamate, saccharin, etc.) , Sodium, etc.), flavorings (vanillin, lactones, etc.), expanding agents (alum, D-potassium hydrogen stannate, etc.), reinforcing agents, emulsifying agents, thickening agents (thickening agents), coating agents, gum base agents, foam inhibitors, solvents, improving agents, etc. It may contain food additives. The additive may be selected according to the type of food and used in an appropriate amount.

As an example of the food composition of the present invention, it may be used as a health drink composition, and in this case, it may contain various flavoring agents or natural carbohydrates, etc. as an additional ingredient, such as a conventional beverage. The natural carbohydrates described above include monosaccharides such as glucose and fructose; Disaccharides such as maltose and sucrose; Polysaccharides such as dextrin and cyclodextrin; It may be a sugar alcohol such as xylitol, sorbitol, and erythritol. Sweeteners include natural sweeteners such as taumatin and stevia extract; Synthetic sweeteners such as saccharin and aspartame can be used. The ratio of the natural carbohydrate may be generally about 0.01 ~ 0.04 g, specifically about 0.02 ~ 0.03 g per 100 ml of the health beverage composition of the present invention.

In addition to the above, health beverage compositions include various nutrients, vitamins, electrolytes, flavoring agents, colorants, pectic acid, salts of pectic acid, alginic acid, salts of alginic acid, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, It may contain alcohol or a carbonation agent. In addition, it may contain flesh for the manufacture of natural fruit juice, fruit juice beverage, or vegetable beverage. These ingredients may be used independently or in combination. Although the ratio of these additives is not very important, it is generally selected from 0.01 to 0.1 parts by weight per 100 parts by weight of the health beverage composition of the present invention.

Another embodiment of the present invention provides a quasi-drug composition for preventing or improving atopic dermatitis comprising a corn beard extract or a fraction thereof.

At this time, the definition of corn beard, extract, fraction, atopic dermatitis, prevention and improvement are as described above.

The term "quasi-drug" of the present invention refers to fibers, rubber products, or the like, which are used for the purpose of treating, alleviating, treating or preventing diseases of humans or animals, weakly acting on the human body or not directly acting on the human body, and Or non-machine or similar, as an item that is one of the preparations used for sterilization, insecticide and similar purposes to prevent infection, and used for the purpose of diagnosing, treating, alleviating, treating or preventing diseases of humans or animals. It refers to items that are not instruments, machines, or devices among the items that are used, and items that are not instruments, machines, or devices among items used for the purpose of pharmacologically affecting the structure and function of humans or animals, and are intended for skin external use and personal hygiene. Includes supplies.

When the corn beard extract of the present invention is added to a quasi-drug composition for the purpose of preventing or improving atopy, the extract may be added as it is or used with other quasi-drug ingredients, and may be appropriately used according to a conventional method. The mixing amount of the active ingredient may be appropriately determined according to the purpose of use (prevention, health or therapeutic treatment).

The quasi-drug composition is not particularly limited thereto, but includes personal hygiene products, external skin preparations, disinfectant cleansers, shower foams, wet tissues, detergent soaps, hand wash, masks or ointments. The external preparation for skin is not particularly limited thereto, but may be specifically prepared and used in the form of an ointment, lotion, spray, patch, cream, powder, suspension, gel or gel. The personal hygiene product is not particularly limited thereto, but may be specifically soap, wet tissue, tissue paper, shampoo, toothpaste, hair care product, air freshener gel, or washing gel.

Another embodiment of the present invention provides a cosmetic composition for preventing or improving atopic dermatitis comprising a corn beard extract or a fraction thereof.

At this time, the definition of corn beard, extract, fraction, atopic dermatitis, prevention and improvement are as described above.

The corn beard extract may contain the extract in an amount of 0.1% to 20% by weight based on the total weight of the composition, as in the pharmaceutical composition. Specifically, it is included in a ratio of 0.1% to 5% by weight, more specifically 0.4 to 0.6% by weight, and even more specifically 0.5% by weight based on the total weight of the composition, but is not limited thereto.

Ingredients included in the cosmetic composition of the present invention include ingredients commonly used in cosmetic compositions in addition to the above extracts, for example, water, surfactants, moisturizers, lower alcohols, chelating agents, fungicides, antioxidants, preservatives, pigments And it may further include one or more additives selected from the group consisting of fragrances.

In addition, the cosmetic composition may be prepared in any conventionally prepared formulation, for example, solution, emulsion, suspension, paste, cream, lotion, gel, powder, spray, surfactant-containing cleansing, oil, soap, It may be formulated as a liquid detergent, bath agent, foundation, makeup base, essence, lotion, foam, pack, softening water, sunscreen cream or sun oil, but is not limited thereto.

When the formulation of the present invention is a solution or emulsion, a solvent, a solubilizing agent or an emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or fatty acid ester of sorbitan.

When the formulation of the present invention is a suspension, liquid diluents such as water, ethanol or propylene glycol as carrier components, ethoxylated isostearyl alcohol, suspending agents such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, crystallites Sex cellulose, aluminum metahydroxide, bentonite, or tracant may be used.

When the formulation of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, or zinc oxide may be used as carrier components. I can.

When the formulation of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder may be used as a carrier component. In particular, in the case of a spray, additionally chlorofluorohydrocarbon, propane / May contain propellants such as butane or dimethyl ether.

When the formulation of the present invention is a surfactant containing cleansing, as a carrier component, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, fatty alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives, or ethoxylated glycerol fatty acid esters may be used.

In addition, the ingredients included in the cosmetic composition may be included in an amount generally used in the field of dermatology.

Since it was confirmed that the corn beard extract of the present invention not only exhibits anti-inflammatory effects, but also suppresses one of the causes of atopic dermatitis, the corn beard extract of the present invention can be widely used in the prevention or treatment of atopic dermatitis. There will be.

1 is a graph showing the result of comparing the effect of corn beard extract on the amount of NO production in LPS-treated macrophages (Raw 264.7).
Figure 2 is a graph showing the results of comparing the effect of corn beard extract on the amount of TNF-α production in LPS-treated macrophages (Raw 264.7).
3 is a graph showing the result of comparing the effect of corn beard extract on TARC production in epithelial cells (HaCaT cells) treated with INF-r and TNF-α.

Hereinafter, the present invention will be described in more detail through examples. However, these examples are for illustrative purposes only, and the scope of the present invention is not limited to these examples.

Example 1: Corn beard extract ( NICS -One, NICS -3) Manufacturing

Corn beard samples were used by collecting corn beard from'Gwangpyeongok' cultivated by the National Institute of Food Science, Rural Development Administration.

Immediately after collecting the sample, cut it into pieces of about 5-10 cm, and add 2000 ml of 95% alcohol (Pretanol A, Reagents Duksan, Gyeonggi-do, Korea) to 1 kg of chopped corn beard to avoid direct sunlight. Extracted for 9 days at a temperature of 25 ℃ in the place not. The extract obtained therefrom was first filtered with cotton wool and then No. 3 Secondary filtration with filter paper and concentrated under reduced pressure to obtain a crude corn extract. The obtained crude cornstarch extract was injected into a column filled with C18 (Preparative C18 reverse phase bulk packing material, 125, 55-105 μm, Waters, Milford, MA) powder, and ethanol (ethanol) wt% in the initial composition of ultrapure water wt% The mobile phase was flowed by using the gradient method with only a bay to obtain a corn beard extract (NICS-1). Corn beard extract (NICS-1) obtained through the above process was re-injected into a C18 column to obtain high purity macin to take a fraction containing a large amount of macin and concentrated under reduced pressure. Corn beard extract (NICS-3) containing a solid mayin was obtained.

Example 2: Cell culture and cell viability measurement

RAW 264.7 cells (mouse macrophage cells, ATCC) and HaCaT cells (human keratinocyte, HaCaT, ATCC) were 10% FBS, penicillin (100 U/ml) and streptomycin (100 μg/ml) at 37°C and 5% CO2 It was cultured with the added DMEM medium. When sufficiently proliferated every 3 days of culture, 1 ml of 0.25% trypsin-EDTA solution was added and treated at room temperature for 1 minute, and then the cells were detached and subcultured. The detached cells were suspended in 10 ml of DMEM culture medium to which 10% FBS was added, and then transferred to a new culture vessel and cultured in a CO ₂ incubator (37° C., 5% CO ₂ ) at a ratio of 1:2.

Cell viability was measured to confirm whether the two prepared corn beard extracts (NICS-1, NICS-3) showed cytotoxicity. The cell viability was determined by diluting the WST-1 reaction solution (cell proliferation reagent WST-1, Roche, Bern, Swiss) to 1/10 in DMEM medium and treating it with 100 µl per well and reacting for 1 hour at 450 nm. The absorbance was measured. As a result, it was confirmed that neither of the two extracts (NICS-1, NICS-3) showed cytotoxicity.

Example 3: Anti-inflammatory effect through NO production inhibition evaluation

NO is known to play an important role in various diseases such as inflammatory response, tumor formation, hypertension, diabetes and dermatitis. In general, it is known to induce an inflammatory response by producing large amounts of NO, an inflammatory mediator, when stimulated by LPS in macrophages. In order to investigate the effect of processing NICS-1 and NICS-3 on RAW 264.7 cells on NO production, sample concentrations of 10, 50 and 100 ㎍/mL were treated, respectively, and stimulated with LPS (1 ㎍/mL) after 30 minutes. Then, after 24 hours incubation, the amount of NO production was confirmed.

Specifically, Raw 264.7 cells of 5×10 ⁴ cells per well were dispensed into a 96-well plate and cultured for 18 hours. After incubation, the sample was treated according to the concentration, and after 30 minutes, LPS (lipopolysaccharide), which is an inflammatory response inducing factor, was treated and incubated for 24 hours. The amount of NO produced was measured in the form of NO ₂ ⁻ present in the cell culture solution using a Grease reagent. 100 µl of the cell culture supernatant and 100 µl of grease reagent were mixed and reacted at room temperature for 10 minutes, and the absorbance was measured at 540 nm. At this time, the NO concentration of the culture medium was compared with the standard of sodium nitrite (Fig. 1).

1 is a graph showing the result of comparing the effect of corn beard extract on the amount of NO production in LPS-treated macrophages (Raw 264.7).

As shown in FIG. 1, it was confirmed that the amount of NO production in the LPS-only treatment group increased significantly compared to the untreated group, but in the group treated with corn salt extract (NICS-1 and NICS-3), the amount of NO production decreased in a concentration-dependent manner. .

Specifically, when treated with LPS alone, the amount of NO produced was 49.43 nM, but when the NICS-1, which was purified once among the extracts, was treated in parallel at a concentration of 100 μg/ml, it was found to decrease by more than 50% to 21.43 nM. In addition, it was found that the amount of NO production in NICS-3, which was purified twice among corn beard extracts, was significantly reduced at 26.25 nM and 3.60 nM concentrations when treated with 50 µg/ml and 100 µg/ml, respectively. In other words, it was found that the inhibitory effect of NO generation by LPS was better when NICS-3 was treated than NICS-1.

Example 4: TNF Anti-inflammatory effect through evaluation of -α production inhibition

TNF-α is a major mediator of the LPS response and plays a key role in the initiation and maintenance of inflammation, showing increased expression in the process of inflammatory lesions, and is particularly closely related to chronic inflammatory diseases. Such TNF-α, through endocrine and exocrine secretion, binds to TNF-α receptors of itself and other macrophages as a ligand, activates various inflammatory-mediated transcription factors, and intensifies inflammation through a mechanism that expresses TNF-α. Therefore, the corn beard extract was analyzed for the effect of TNF-α secretion in RAW 264.7 cells.

Specifically, Raw 264.7 cells of 1×10 ⁶ cells per well were dispensed into a 48-well plate and cultured for 24 hours. After culture, the cells were starved for 12 hours, and then LPS 1 µg/ml and each corn beard extract (0, 10, 50, 100 µg/ml) were treated alone or in combination, and cultured for 24 hours. The medium of the cultured cells was collected and the amount of TNF-α was measured by ELISA. In addition, the cells attached to the floor were washed with PBS and then lysed with 1N sodium hydroxide (NaOH) to measure the total protein amount to measure the amount of TNF-α production for a certain protein. At this time, the amount of each TNF-α and the amount of protein were measured according to the calibration line (Fig. 2).

Figure 2 is a graph showing the results of comparing the effect of corn beard extract on the amount of TNF-α production in LPS-treated macrophages (Raw 264.7).

As shown in FIG. 2, the LPS alone treatment group showed a high TNF-α production amount of 3401.09 pg/ml, but as a result of treatment with corn beard extracts (NICS-1 and NICS-3), respectively, 1862.76 and at 100 µg/ml It was inhibited at 1364.25 pg/ml. In particular, in the case of NICS-3, it was confirmed that the concentration-dependently decreased production amount was 2621.80 pg/ml in the 10 µg/ml treatment group and 2195.97 pg/ml in the 50 µg/ml treatment group.

From the above results, it was found that corn beard extracts (NICS-1 and NICS-3) inhibit TNF-α secretion in RAW 264.7 cells and are involved in anti-inflammatory function.

Example 5: Atopic dermatitis improvement effect

The effect of corn beard extract on the production of thymus and activation regualted chemokine (TAC), a kind of inflammatory cytokine (Th2 chemokine) produced in epithelial cells (HaCaT cells), was analyzed.

Specifically, HaCaT cells, which are epithelial cells, were dispensed into a 48-well plate at 1×10 ⁶ cells per well and cultured for 24 hours. The medium was removed, 10 ng/mL of INF-r, 10 ng/mL of TNF-α, and each corn beard extract were diluted in the medium at respective concentrations, followed by treatment. After 24 hours of incubation, the culture medium was taken and the amount of TARC secretion was measured using a Human TARC immunoassay kit (Immunoassay kit, R&D systems, PDDN00), and the measured TARC amount was corrected to the total protein amount (FIG. 3).

3 is a graph showing the result of comparing the effect of corn beard extract on TARC production in epithelial cells (HaCaT cells) treated with INF-r and TNF-α.

As shown in FIG. 3, compared to the control group without any treatment, the experimental group treated with IFN-γ and TNF-α showed a significant increase in TARC production, so that treatment with IFN-γ and TNF-α increased atopy of HaCaT cells. It can be seen that it was effectively induced.

In addition, in the case of NICS-1, 925.3%, 580.9%, and 161.8% of TARC were produced, respectively, compared to the control group not treated with IFN-γ and TNF-α, which decreased in a concentration-dependent manner, and in the case of NICS-3, the control group In contrast, 301.5%, 1210.8% and 924.9% of TARC were generated, respectively, and it was confirmed that the concentration-dependent decrease was similar to that of NICS-1. That is, it was found that the corn beard extract (NICS-1 and NICS-3) of the present invention exhibits an effect of inhibiting TARC production in HaCaT cells, which are epithelial cells.

From the above results, it was found that the corn beard extract of the present invention can exhibit an effect of treating atopic dermatitis by inhibiting the production of inflammatory cytokines produced in epithelial cells.

From the above description, those skilled in the art to which the present invention pertains will be able to understand that the present invention can be implemented in other specific forms without changing the technical spirit or essential features thereof. In this regard, the embodiments described above are illustrative in all respects and should be understood as non-limiting. The scope of the present invention should be construed that all changes or modifications derived from the meaning and scope of the claims to be described later rather than the above detailed description, and equivalent concepts thereof, are included in the scope of the present invention.

Claims (13)

A pharmaceutical composition for the prevention or treatment of atopic dermatitis, comprising a corn beard extract or a fraction thereof.
The method of claim 1,
The corn beard extract is to reduce the level of NO (nitric oxide) and TNF-α (tumor necrosis factor-α) produced in macrophages stimulated with LPS (lipopolysaccharide), a pharmaceutical composition for the prevention or treatment of atopic dermatitis .
The method of claim 2,
The macrophages are RAW 264.7 cells, a pharmaceutical composition for the prevention or treatment of atopic dermatitis.
The method of claim 1,
The corn beard extract is to reduce the level of inflammatory cytokines produced in epithelial cells stimulated with IFN-γ (Interferon-γ) and TNF-α (tumor necrosis factor-α), for the prevention or treatment of atopic dermatitis Pharmaceutical composition.
The method of claim 4,
Wherein the epithelial cells are HaCaT cells, a pharmaceutical composition for the prevention or treatment of atopic dermatitis.
The method of claim 4,
The inflammatory cytokine is TARC (thymus and activation regualted chemokine) that is, a pharmaceutical composition for the prevention or treatment of atopic dermatitis.
The method of claim 1,
The extract is obtained by extracting corn beard with one or more solvents selected from the group consisting of water, alcohols having 1 to 4 carbon atoms, and mixed solvents thereof.
The method of claim 1,
The fraction is selected from the group consisting of water, alcohol having 1 to 4 carbon atoms, hexane (Hexane), ethyl acetate (Ethyl acetate), chloroform (Chloroform), dichloromethane (Dichloromethane) and a mixed solvent thereof. A pharmaceutical composition for the prevention or treatment of atopic dermatitis, which is obtained by fractionation with a solvent.
The method of claim 1,
The composition further comprises a pharmaceutically acceptable carrier, excipient or diluent, a pharmaceutical composition for the prevention or treatment of atopic dermatitis.
A method of treating atopic dermatitis, comprising administering the pharmaceutical composition of any one of claims 1 to 9 to an individual suspected of having atopic dermatitis, excluding humans.
A food composition for improving atopic dermatitis comprising a corn beard extract or a fraction thereof.
A quasi-drug composition for the prevention or improvement of atopic dermatitis comprising a corn beard extract or a fraction thereof.
A cosmetic composition for the prevention or improvement of atopic dermatitis comprising a corn beard extract or a fraction thereof.

Images